Wat is de prijs voor Coya Therapeutics, Inc. (COYA)

Het prijs van Coya Therapeutics, Inc. (COYA) is $4.83

Wat is de marktkapitalisatie voor Coya Therapeutics, Inc. (COYA)

Marktkapitalisatie voorCoya Therapeutics, Inc. (COYA) is $113.30M

Coya Therapeutics, Inc. (COYA) K/B-verhouding

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.

Jaar	P/B-ratio	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

P/B-ratio

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	P/B-ratio	Verschil in P/B-ratio	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Moderna, Inc. MRNA.US	3.7087	-	US
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

P/B-ratio

Verschil in P/B-ratio

Land